There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT – Research Report) and Crispr ...

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. securities between June 30, 2024 and January ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Gilead Sciences reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $7.56 billion which beat the analyst consensus estimate ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

One bad year continues to haunt university endowments’ performance. U.S. school funds had a strong fiscal year, rising an average 11.2% in the 12 months through June 30. “Fiscal 2022 is going to stick ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...